JP2013538845A - デフェラシロクスを含む医薬組成物 - Google Patents

デフェラシロクスを含む医薬組成物 Download PDF

Info

Publication number
JP2013538845A
JP2013538845A JP2013530795A JP2013530795A JP2013538845A JP 2013538845 A JP2013538845 A JP 2013538845A JP 2013530795 A JP2013530795 A JP 2013530795A JP 2013530795 A JP2013530795 A JP 2013530795A JP 2013538845 A JP2013538845 A JP 2013538845A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
deferasirox
inhibitor
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013530795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538845A5 (enExample
Inventor
マルホトラ ゲエナ
マドフカル プランダレ ドル．スフリニバス
Original Assignee
シプラ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802316&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013538845(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シプラ・リミテッド filed Critical シプラ・リミテッド
Publication of JP2013538845A publication Critical patent/JP2013538845A/ja
Publication of JP2013538845A5 publication Critical patent/JP2013538845A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013530795A 2010-10-01 2011-09-30 デフェラシロクスを含む医薬組成物 Pending JP2013538845A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2750/MUM/2010 2010-10-01
IN2750MU2010 2010-10-01
PCT/GB2011/001428 WO2012042224A2 (en) 2010-10-01 2011-09-30 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
JP2013538845A true JP2013538845A (ja) 2013-10-17
JP2013538845A5 JP2013538845A5 (enExample) 2014-09-18

Family

ID=44802316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530795A Pending JP2013538845A (ja) 2010-10-01 2011-09-30 デフェラシロクスを含む医薬組成物

Country Status (18)

Country Link
US (3) US20140147503A1 (enExample)
EP (1) EP2621471A2 (enExample)
JP (1) JP2013538845A (enExample)
KR (1) KR20140011300A (enExample)
CN (1) CN103209687A (enExample)
AP (1) AP3578A (enExample)
AU (1) AU2011309872B2 (enExample)
BR (1) BR112013007276A2 (enExample)
CA (1) CA2812505A1 (enExample)
EC (1) ECSP13012534A (enExample)
IL (1) IL225457A (enExample)
MX (1) MX2013003522A (enExample)
MY (1) MY165826A (enExample)
NZ (1) NZ608380A (enExample)
PE (2) PE20140166A1 (enExample)
RU (1) RU2589842C2 (enExample)
WO (1) WO2012042224A2 (enExample)
ZA (1) ZA201302092B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10946066B2 (en) 2010-11-09 2021-03-16 Cornell University Methods for organ regeneration

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015003729A (es) 2012-11-12 2015-06-15 Cipla Ltd Composiciones farmaceuticas de dosis fija que comprende deferasirox y deferiprona.
SI2964202T1 (sl) * 2013-03-08 2019-02-28 Novartis Ag Peroralne formulacije deferasiroksa
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
CN105377256A (zh) * 2013-05-10 2016-03-02 奇普拉股份有限公司 低剂量药物组合物
TWI697337B (zh) * 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IN2014MU00303A (enExample) * 2014-01-28 2015-09-11 Cipla Ltd
IN2014MU00916A (enExample) * 2014-03-20 2015-09-25 Cipla Ltd
KR20160088965A (ko) * 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
EP3310354A4 (en) * 2015-06-17 2018-12-12 Dispersol Technologies, LLC Improved formulations of deferasirox and methods of making the same
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
EP3481390A4 (en) * 2016-07-05 2020-03-04 Jubilant Generics Limited PHARMACEUTICAL COMPOSITION WITH IMMEDIATE RELEASE OF IRON CHELATE IMAGERS
CN107693516B (zh) * 2016-08-08 2020-06-26 上海宣泰医药科技有限公司 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
WO2018059922A1 (en) 2016-09-30 2018-04-05 Synthon B.V. Pharmaceutical composition comprising deferasirox
WO2018187728A1 (en) 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
US12419884B2 (en) 2018-08-06 2025-09-23 Brigham Young University Compositions and methods for treating iron overload
AU2021276611A1 (en) 2020-05-18 2022-12-15 Orexo Ab New pharmaceutical composition for drug delivery
JP2024541470A (ja) 2021-11-25 2024-11-08 オレクソ・アクチエボラゲット アドレナリンを含む医薬組成物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
CN115400088B (zh) * 2022-09-06 2023-07-07 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520443A (ja) * 2000-11-20 2004-07-08 エラン ファーマ インターナショナル，リミティド 表面安定剤として共重合体を含むナノ粒子組成物
JP2005530712A (ja) * 2002-03-20 2005-10-13 エラン ファーマ インターナショナル，リミティド 血管新生抑制剤のナノ粒子組成物
WO2009067557A1 (en) * 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1708343A1 (ru) * 1989-09-22 1992-01-30 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ получени твердых лекарственных форм
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
US6509380B1 (en) * 2001-12-14 2003-01-21 Marshall University Research Corporation Method of treating iron overload with acetaminophen
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US7531351B2 (en) * 2004-06-14 2009-05-12 Probiogen Ag Liquid-gas-phase exposure reactor for cell culturing
RU2008119410A (ru) * 2005-10-19 2009-11-27 Новартис АГ (CH) Диспергируемые таблетки, включающие деферасирокс
US20090016359A1 (en) * 2007-07-11 2009-01-15 Samsung Electronics Co., Ltd. System and method for processing high definition video data to be transmitted over a wireless medium
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) * 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520443A (ja) * 2000-11-20 2004-07-08 エラン ファーマ インターナショナル，リミティド 表面安定剤として共重合体を含むナノ粒子組成物
JP2005530712A (ja) * 2002-03-20 2005-10-13 エラン ファーマ インターナショナル，リミティド 血管新生抑制剤のナノ粒子組成物
WO2009067557A1 (en) * 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015028933; 難溶性薬物の物性評価と製剤設計の新展開 , 201001, ｐ．１４１-１５０ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10946066B2 (en) 2010-11-09 2021-03-16 Cornell University Methods for organ regeneration

Also Published As

Publication number Publication date
PE20140166A1 (es) 2014-02-17
EP2621471A2 (en) 2013-08-07
RU2589842C2 (ru) 2016-07-10
KR20140011300A (ko) 2014-01-28
WO2012042224A3 (en) 2012-08-09
WO2012042224A8 (en) 2013-04-11
NZ608380A (en) 2014-10-31
AP2013006785A0 (en) 2013-04-30
AP3578A (en) 2016-02-08
IL225457A0 (en) 2013-06-27
MY165826A (en) 2018-05-17
CN103209687A (zh) 2013-07-17
US20180311216A1 (en) 2018-11-01
ZA201302092B (en) 2013-11-27
US20160324831A1 (en) 2016-11-10
WO2012042224A2 (en) 2012-04-05
RU2013120275A (ru) 2014-11-20
PE20170468A1 (es) 2017-04-26
US20140147503A1 (en) 2014-05-29
MX2013003522A (es) 2013-05-22
ECSP13012534A (es) 2013-10-31
IL225457A (en) 2017-04-30
AU2011309872B2 (en) 2014-09-04
CA2812505A1 (en) 2012-04-05
BR112013007276A2 (pt) 2016-06-14
AU2011309872A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
JP2013538845A (ja) デフェラシロクスを含む医薬組成物
AU2011244783B2 (en) Pharmaceutical compositions
US20200163882A1 (en) Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists
EP2442799B1 (en) Solid pharmaceutical composition comprising rivaroxaban
JP5484910B2 (ja) レバプラザン含有の固体分散体及びその製造方法
DK2421540T3 (en) Hitherto unknown formulation with meloxicam
US9889144B2 (en) Abiraterone acetate formulation and methods of use
CN101801347A (zh) 包含二氢吡啶类钙通道拮抗剂的改进的药物组合物及其制备方法
JP2013518860A (ja) Ｎ−（２−クロロ−６−メチルフェニル）−２−［［６−［４−（２−ヒドロキシエチル）−１−ピペラジニル］−２−メチル−４−ピリミジニル］アミノ］−５−チアゾールカルボサキミドを含む医薬組成物
JP2015536970A (ja) デフェラシロクス及びデフェリプロンを含む固定用量医薬組成物
JP2016518398A (ja) 低用量医薬組成物
JP2012516346A (ja) ピリドピリミジノンの経口用固体製剤
WO2012100948A1 (en) Pharmaceutical compositions comprising tasocitinib
US20100104634A1 (en) Pharmaceutical compositions of entacapone
OA16350A (en) Pharmaceutical composition comprising deferasirox.
WO2007064084A1 (en) Granules containing pranlukast and processes for the preparation thereof
OA16372A (en) Reclaimer machine.
US20120195933A1 (en) Pharmaceutical compositions comprising tasocitinib
MX2012012084A (es) Composicion farmaceutica.
AU2016213775A1 (en) A Novel Formulation of Meloxicam
HK1141726A (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160412